Better Health for All

CARGO Therapeutics is a biotechnology company focused on developing CAR T-cell therapies for cancer patients.

aiming to provide potentially curative cell therapies and address limitations of existing treatments. This aligns with the entire business being devoted to health improvement. The company has no revenue from products with direct health impacts. However, its lead program, firi-cel, was discontinued due to safety complications, with 18% of 51 patients in the Phase 2 trial developing grade 3 or higher immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), including grade 4 and 5 serious adverse events. This represents a significant safety incident. While CARGO plans to present an analysis of the FIRCE-1 Phase 2 study at a future medical conference, this is a reactive safety approach. The company is advancing other programs like CRG-023 and a novel allogeneic platform, but there is no specific quantitative evidence of R&D investment as a percentage of budget. In January 2025, CARGO implemented a workforce reduction of approximately 50% of its 170 full-time employees, indicating a substantial reduction in healthcare workforce support. The company's clinical trials have focused on specific patient groups (e.g., LBCL patients relapsed or refractory to CD19 CAR T-cell therapy) without explicit mention of broader diversity initiatives, suggesting limited diversity in trial populations. There is no evidence regarding price accessibility, vulnerable reach, or pharma patent flexibility.

Fair Pay & Worker Respect

The provided articles do not contain specific, quantifiable data points for any of the KPIs related to Fair Pay & Worker Respect. While some articles mention layoffs

, these are involuntary workforce reductions and do not provide data on voluntary turnover. Salary ranges are mentioned , but there is no information on living wage coverage or a comparison to local living wage benchmarks. Similarly, an average compensation rating of 1/5 stars is noted , but this is not an employee engagement score on the required 100-point scale. Multiple articles explicitly state that no regulatory actions, violations, fines, or compliance issues are mentioned , which means there is no evidence to score the labor violation incidents KPI. Therefore, all KPIs must be omitted due to lack of direct evidence.

Honest & Fair Business

No specific, concrete data points were found in the provided articles for any of the KPIs related to Honest & Fair Business. The articles mention ongoing investigations by law firms (Halper Sadeh LLC and DJS Law Group) into CARGO Therapeutics, Inc. regarding the fairness of a sale to Concentra Biosciences and alleged misleading statements or failure to disclose information pertinent to investors concerning the discontinuation of a clinical study.

However, these are investigations and allegations, not confirmed fines, scores from benchmarks, quantifiable percentages, or resolution times that map to the rubric's thresholds. Therefore, all KPIs are omitted due to lack of direct evidence.

Kind to Animals

CARGO Therapeutics Inc. conducts pre-clinical studies on animals to assess product safety, with a 2023 report explicitly stating the use of a mouse model.

The company does not appear to be certified cruelty-free. No information is available regarding alternative testing usage, animal testing policy, animal testing volume, or R&D investment in animal-free technologies. Additionally, there is no data on humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.

Planet-Friendly Business

No data related to CARGO Therapeutics, Inc. (CRGX.US) or planet-friendly business metrics such as emissions, renewable energy, water use, green certifications, waste diversion, or climate-related initiatives was found in the provided articles.

The articles focused on corporate acquisition and clinical trial updates, or on the ESG initiatives of a different company (Cargo-Partner).

Respect for Cultures & Communities

The provided articles focus on CARGO Therapeutics' core business operations, including its clinical-stage biotechnology, CAR T-cell therapies, corporate strategy, and financial updates.

No information is available regarding the company's engagement with local or indigenous communities, cultural impact assessments, community investments, or any other metrics related to the 'Respect for Cultures & Communities' value.

Safe & Smart Tech

The company's 2024-03-21 10-K filing states that no data breaches or incidents of unauthorized data use have been reported.

It also indicates that no known cybersecurity threats have materially affected or are likely to affect the company. The company uses a third-party SOC partner for monitoring and response, and privacy principles are integrated into its overall enterprise risk management program. Employee security and privacy training, including phishing campaigns, are conducted, but no specific metrics on their effectiveness are provided.